anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The activation of the NLRP3 inflammasome has been linked to several inflammatory and autoinflammatory diseases. Despite cases of potential hearing improvement in immune-mediated diseases, direct evidence of the efficacy of targeting this mechanism in the inner ear is still lacking. Previously, we discovered that macrophages are associated with Sensorineural Hearing loss (SNHL) in Chronic Suppurative Otitis Media (CSOM), the leading cause of this permanent hearing loss in the developing world and incurring costs of $4 to $11 billion dollars in the United States. However, the underlying mechanism remained unknown. Here, we investigate how macrophages drive permanent hearing loss in CSOM. We first confirmed the occurrence of NLRP3 inflammasome activation in cochlear macrophages in CSOM. We then revealed that Outer Hair Cells (OHCs) were protected in CSOM by macrophage depletion and subsequently confirmed the same protection in the NLRP3 knockout condition. Furthermore, we showed that therapeutic inhibition of NLRP3 inflammasome activation and downstream inhibition of IL-1β protects OHCs in CSOM. Collectively, our data demonstrates that the main driver for hearing loss in CSOM is NLRP3 inflammasome activation in cochlear macrophages and this is therapeutically targetable, leading the way for the development of interventions to prevent the leading cause of permanent hearing loss and a costly disease in the developed world.
<P>PROBLEM TO BE SOLVED: To provide a collagen production promotor promoting the production of the collagen by a collagen-producing cell, and comprising a component originated from a plant mild to the body, and to provide a cosmetic, and an oral composition for promoting the collagen production.  <P>SOLUTION: The collagen production promotor contains piceatannol as an active ingredient for promoting the collagen production. The piceatannol is preferably originated from a natural product, and is more preferably originated from a plant. An extract of a seed of a passion fruit is preferably used because the seed of the passion fruit contains the piceatannol in high content. The invention is preferably usable for the cosmetic or the oral composition for promoting the production of the collagen.  <P>COPYRIGHT: (C)2010,JPO&INPIT
FIELD: medicine. SUBSTANCE: composition is proposed in two variants. By variant 1 composition has wheat embryos and sugar taken in the following ratio of components, wt.%: wheat embryos, 50-90; sugar, 50-10. By variant 2 composition has additionally licorice dry root extract taken in the amount 12-5% and microcrystalline cellulose taken in the amount 13-5% of sugar weight. Proposed agent shows the broad therapeutic effect in different pathological states as an agent eliciting the general tonic and stimulating action. EFFECT: enhanced effectiveness of composition. 2 cl, 4 ex
Human overgrowth disorders are characterized by excessive prenatal and/or postnatal growth of various tissues. These disorders often present with tall stature, macrocephaly, and/or abdominal organomegaly and are sometimes associated with additional phenotypic abnormalities such as intellectual disability and increased cancer risk. As the genetic etiology of these disorders have been elucidated, a surprising pattern has emerged. Multiple monogenic overgrowth syndromes result from variants in epigenetic regulators: variants in histone methyltransferases NSD1 and EZH2 cause Sotos syndrome and Weaver syndrome, respectively, variants in DNA methyltransferase DNMT3A cause Tatton-Brown-Rahman syndrome, and variants in chromatin remodeler CHD8 cause an autism spectrum disorder with overgrowth. In addition, very recently, a variant in histone reader protein SPIN4 was identified in a new X-linked overgrowth disorder. In this review, we discuss the genetics of these overgrowth disorders and explore possible common underlying mechanisms by which epigenetic pathways regulate human body size.
Patients will be followed up until development of hepatitis flare or at 2 years after study recruitment. We plan to recruit 150 patients for the prospective cohort.
The invention discloses an interference RNA for specifically inhibiting ESCCAL_1 expression. The sequence of the interference RNA is shown in SEQ ID NO. 5. The invention discloses a method for preparing an interference cell strain by virtue of the interference RNA simultaneously. The invention provides an interference RNA for specifically inhibiting ESCCAL_1 expression for the first time, the interference RNA is prepared to obtain the interference cell strain, the interference cell strain is subjected to an animal experiment and compared with a control group, and the result indicates that the interference cell strain is capable of obviously inhibiting ESCCAL_1 expression, and then the growth and migration of tumours are inhibited. The interference RNA has an important reference value in the development of anti-tumour medicines.
Preoperative localization of the lung nodule will be carried out in the radiology department on the day of surgery using local anesthesia. CT-guided hook-wire or methyl blue dye will be placed percutaneously through a 22-gauge needle with the distal end deep to the nodule. The patient will then be taken to the operating room, where under general anesthesia with lung isolation, the nodule will be removed by wedge excision with endostaplers (Endo-GIA-II, United States Surgical,Norwalk, Conn; Echelon Endostapler, Ethicon Endo-Surgery, Cincinnati,Ohio) under the guidance of preoperative lung marking. If the lesion could not be excised using the VATS technique, the patient underwent an open thoracotomy.
There are case reports in the medical literature of sodium nitrite in conjunction with sodium thiosulfate being administered to pediatric patients with cyanide poisoning; however, there have been no clinical studies to evaluate the safety or efficacy of sodium nitrite in the pediatric population. As for adult patients, dosing recommendations for pediatric patients have been based on theoretical calculations of antidote detoxifying potential, extrapolation from animal experiments, and a small number of human case reports.

Sodium nitrite must be used with caution in patients less than 6 months of age because they may be at higher risk of developing severe methemoglobinemia compared to older children and adults. The presence of fetal hemoglobin, which is oxidized to methemoglobin more easily than adult hemoglobin, and lower methemoglobin reductase levels compared to older children and adults may contribute to risk.

Mortality attributed to sodium nitrite was reported following administration of an adult dose (300 mg IV followed by a second dose of 150 mg) to a 17-month old child. [see Dosage and Administration (2), Warnings and Precautions, (5), Adverse Reactions (6)]
Specific gene mutations have become targets for specific therapies. For example lung adenocarcinomas with an EGFR (epidermal growth factor receptor) mutation can be targeted with an EGFR tyrosine kinase inhibitor achieve striking and durable responses and improved survival. Another example is the identification of the echinoderm microtubule-associated protein-like 4/anaplastic lymphoma kinase (ALK) gene fusions which have led to significant therapeutic gains in the small percentage of patients with lung adenocarcinoma whose cancers exhibit this mutation. Specific mutations have been found in colon cancer and specific drugs targeting these gene alterations are in development. As future therapeutic protocols specific for these mutations are developed, patients who agree may be notified of their eligibility for these studies.

The aims of this study are to link mutational analyses with clinical outcome. It is recommended that patients receive 8 cycles of mFOLFOX6 (modified FOLFOX) and 50.4 Gy radiation with concurrent fluoropyrimidine.
PURPOSE:The titled pharmaceutical preparation containing ignavine and/or its acid addition salt. CONSTITUTION:An antiallergic containing a compound shown by the formula (alkaloid contained in Aconitum japonicum Thumb.; melting point: 228-230 deg.C; having improved antipyretic, analgesic, and anti-inflammatory action) and/or its acid addition salt (e.g., inorganic acid salt such as hydrochloride, sulfate, etc., organic acid salt such as maleate, fumarate, etc.) as an active ingredient. The dosage form is a medicine for internal use such as tablet, powder, capsule, injection, a medicine for external use, etc. A dose is 100mg/time in the case of oral administration, and <=4mg/time in the case of injection. The compound shown by the formula inhibits delayed type allergic reactions (e.g., tuberculin type reaction, allotransplantation rejection, contagious hypersensitivity reaction of the skin, etc.) in the strongest way.
The Transcendental Meditation program is described as a simple natural technique practiced for 20 minutes twice daily for deep rest and relaxation. Previous studies have shown its feasibility, validity, and reliability in Blacks at risk for CVD.
Pembrolizumab 200 mg IV every 3 weeks for up to 35 cycles will be administered in combination with IMM60 IV every 3 weeks for up to 6 cycles. The IMM60 dose will be determined based on the results of the Phase 1 dose escalation safety cohorts.
This study aimed to determine whether a polyphenol-rich cranberry beverage affects skin properties, lipids, and the microbiome in women using a randomized, double-blinded, placebo-controlled, cross-over design. Twenty-two women with Fitzpatrick skin types 2-3 were randomized to drink a cranberry beverage or placebo for six weeks. After a 21-day washout, they consumed the opposite beverage for six weeks. Six weeks of cranberry beverage significantly reduced UVB-induced erythema, improved net elasticity on the face and forearm, smoothness on the face, and gross elasticity on the forearm compared to the placebo. When stratified by age, these effects of the cranberry beverage were primarily observed in women >40 years old. SOD activities were improved after six weeks of cranberry beverage consumption compared to the placebo, while glutathione peroxide and TNF-α were improved compared to baseline. These effects were found to differ by age group. Skin lipid composition was modulated by both the cranberry beverage and the placebo. Cranberry beverages did not change α- or β-diversity but altered the abundance of several skin microbes at the species and strain level. Consumption of a cranberry beverage for six weeks improved specific skin properties and oxidative stress and modulated skin lipids and microbiome compared to placebo.
Introduction: Aneurysmal subarachnoid hemorrhage (SAH) is a devastating form of stroke, which often causes acute hydrocephalus requiring the insertion of an external ventricular drain (EVD). A major complication of aneurysmal SAH is delayed cerebral ischemia (DCI), which corresponds to the occurrence of an ischemic stroke up to 21 days after the aneurysm rupture. There are currently only few ways to prevent it. As DCI is linked to the presence of blood within the subarachnoid space, it has been hypothesized that removing this blood may decrease the risk of DCI. It could be obtained by injecting a fibrinolytic agent through the EVD, a therapeutic strategy named intraventricular fibrinolysis (IVF). There are several evidences, both in preclinical and in clinical studies that IVF controls the phenomenon that are leading to DCI. It has notably been shown in Phase I and Phase II trial that IVF in aneurysmal SAH is safe and may decrease the risk of DCI, with a trend to improve the rate of good functional outcome by about 10%. Here, the investigators propose to conduct a phase III trial to provide a clear evaluation of the impact of IVF after aneurysmal SAH.

Materials and methods: this study will include patients with aneurysmal SAH requiring external ventricular drainage. The investigators will perform a pragmatic randomized controlled trial: compare the standard of care, i.e. the EVD alone, to the experimental treatment, i.e. IVF, with an open design. After exclusion of the aneurysm, patients will be randomly allocated to receive either EVD alone or EVD+IVF (72 hours, 9 doses). The primary outcome will be the proportion of patients without severe disability 6 months after the aneurysm rupture, as evaluated by the modified Rankin Scale (mRS). The investigators plan to include 440 patients, to show an increase of the rate of good functional outcome of 10% in the EVD+IVF group compared to the EVD alone group (α=0.05 and β=0.8). To obtain such sample, a multicenter trial is mandatory, and to date 16 centers accepted to participate. Each center will include one patient per month, and the inclusion period is to last 48 months.
The intervention group will receive a free pack of one-week NRT. The nurse will help the subject to decide which NRT product (patch, gum and lozenge) he/she can use and advise how to use the NRT based on his/her smoking habit and amount of cigarette consumption, followed by the delivery of the sampling, instructions of using the NRT sampling, an education card about NRT and a 12-page smoking cessation booklet (Figure 1). Based on the experience in the previous trials, the choice of NRT (either patch, lozenge or gum) will be made according to subject's preference, and the counsellors will provide medication counselling \[25-27\]. If the subject is willing to continue the counselling at recruitment, the ambassador will further introduce the NRT's side effects, adherence and effectiveness (Table 1). Otherwise, the ambassador will contact the subject for providing these details and enquiring the usage through telephone within 2 days.
Participants (Cohort 1) received rabies vaccine at Month 0 and placebo at 6 and 12 months. Participants (Cohort 2) received placebo at 0, 6, and 12 months.
The HLA matched donor will receive granulocyte colony-stimulating factor (G-CSF) with apheresis collections of PBPC on day 5 and day 6 if required. G-CSF will be administered based on body weight for at least 5, and up to 7 days, subcutaneously.
Neutrophils are the most abundant leukocytes in human blood and play a primary role in resistance against invading microorganisms and in the acute inflammatory response. However, their role in colitis and colitis-associated colorectal cancer is still under debate. This study aims to dissect the role of neutrophils in these pathologic contexts by using a rigorous genetic approach. Neutrophil-deficient mice (Csf3r-/- mice) were used in classic models of colitis and colitis-associated colorectal cancer and the role of neutrophils was assessed by histologic, cellular, and molecular analyses coupled with adoptive cell transfer. We also performed correlative analyses using human datasets. Csf3r-/- mice showed increased susceptibility to colitis and colitis-associated colorectal cancer compared with control Csf3r+/+ mice and adoptive transfer of neutrophils in Csf3r-/- mice reverted the phenotype. In colitis, Csf3r-/- mice showed increased bacterial invasion and a reduced number of healing ulcers in the colon, indicating a compromised regenerative capacity of epithelial cells. Neutrophils were essential for γδ T-cell polarization and IL22 production. In patients with ulcerative colitis, expression of CSF3R was positively correlated with IL22 and IL23 expression. Moreover, gene signatures associated with epithelial-cell development, proliferation, and antimicrobial response were enriched in CSF3Rhigh patients. Our data support a model where neutrophils mediate protection against intestinal inflammation and colitis-associated colorectal cancer by controlling the intestinal microbiota and driving the activation of an IL22-dependent tissue repair pathway.
The recommended dose of WELCHOL Tablets in adults, whether used as monotherapy or in combination with a statin, is 6 tablets once daily or 3 tablets twice daily. WELCHOL Tablets should be taken with a meal and liquid. 

The recommended dose of WELCHOL for Oral Suspension, in adults and children 10 to 17 years of age, is one 3.75 gram packet once daily or one 1.875 gram packet twice daily. To prepare, empty the entire contents of one packet into a glass or cup. Add ½ to 1 cup (4 to 8 ounces) of water, fruit juice, or diet soft drinks. Stir well and drink. WELCHOL for Oral Suspension should be taken with meals. To avoid esophageal distress, WELCHOL for Oral Suspension should not be taken in its dry form. Due to tablet size, it is recommended that any patient who has difficulty swallowing tablets use WELCHOL for Oral Suspension.

WELCHOL can be dosed at the same time as a statin or the two drugs can be dosed apart [See Clinical Studies (14.1)].

After initiation of WELCHOL, lipid levels should be analyzed within 4 to 6 weeks.
Disclosed are an anti-irritation composition, a preparation method therefor and the application thereof. The anti-irritation composition comprises peach gum, cactus, Centella asiatica, and Semen plantaginis. The material composition is simple, the preparation process is simple, all the components interact with each other, and skin irritation caused by cosmetics raw materials can be effectively resisted. Efficacy evaluation experiments have proven that the anti-irritation composition of the present invention can antagonize lactic acid irritation, improve the rate of inhibition of red blood cell hemolysis caused by sodium dodecyl sulfate (SDS), reduce chick chorioallantoic membrane irritation caused by SDS, and antagonize various irritation sources in cosmetics. When the composition is applied to cosmetics, the composition is expected to have an anti-irritation efficacy and can antagonize skin irritation caused by various irritation sources, such as acidic substances, surfactants, flavors and fragrances, preservatives etc. in cosmetics raw materials.
PURPOSE:To provide a megakaryocyte amplification promoting agent containing beta2-microglobulin as an active component and useful for the prevention and treatment of thrombocytopenia. CONSTITUTION:This composition contains beta2-microglobulin or its derivative as an active component. beta2-Microglobulin constitutes the light chain between two chains constituting a histocompatible antigen and is a protein having a molecular weight of about 11,500 in the case of beta2-microglobulin originated from mouse or human. beta2-Microglobulin originated from mammals, especially mouse or human is preferable. It can be obtained in purified form from a cultured supernatant of the lymphocyte of the animal, urine or extract of tissue (liver or placenta) of a patient of renal insufficiency or an expression product of a transformant obtained by integrating a beta2-microglobulin gene in a proper host cell. The agent is safe and effective because beta2-microglobulin is free from antigenicity. The composition can be used as a substitution assistant for the treatment of leukemia or thrombocyte transfusion or the proliferation culture of infusion marrow in vitro.
A thermal accelerant can be used as a drug delivery vehicle to deliver one or more drugs to a target site. For example, in some embodiments, a carrier such as albumin or human serum albumin (HSA) can be impregnated with, or covalently attached to, an anti¬ tumor agent and delivered to a location proximate to a tumor of a patient. The carrier can be exposed to an energy source that structurally alters the carrier and releases the agent therefrom. The sources of energy can include one or more of microwave, radiofrequency, electrical pulse (electroporation) or sonar (HIFU or histotripsy). In some embodiments, the anti-tumor agent can be delayed release such that a portion of the agent is released from the carrier over an extended period of time. The incorporation of an anti-tumor agent in a thermal accelerant provides a thermal ablation-drug delivery combination therapy (e.g.,a thermally-activated combination therapy).
Participants will receive treatment four times a week for two weeks and three times a week for two weeks. Participants will be treated with major points: Yintang, Du20 (Bai Hui), LI4 (He Gu), LR3 (Tai Chong), ST36 (Zusanli) (front treatment) or GB20 (Feng Chi), SP6 (Sanyinjiao), BL15 (Xin Shu), BL18 (Gan Shu), BL23 (Shen Shu) (back treatment). The position of the treatment will alternate between sessions such that the first session will be on the back, with the next session on the front. In addition to the 5 required points, acupuncturist will be allowed to choose 1-3 more points. The supplemental points may be chosen from the following: HT7 (Shenmen), PC6 (Neiguan), SI3 (Hou Xi), RN6 (Qi Hai), KI 3 (Taixi), KI 6 (Zhao Hai), SP10 (Xue Hai), BL14 (Jue Yin Shu), BL17 (Ge Shu), BL20 (Pi Shu).
A wetting alert system having a sensor with a replaceable element, a transceiver with an input port for a legacy wireless receiver, an alert processor, an alert presenter, and a server. The replaceable element wicks fluid from a body exit, completing a circuit and sending an output signal. The alert processor determines if the output signal describes wetting; adjusts electrical properties of the sensor; turns off the sensor, preventing injury; and selects alert presenters to present alerts to caregivers, in series, parallel, or combinations. Alert presenters determine if caregivers are responding, and inform the alert processor. If caregivers fail to respond, the alert processor fails over the alert to other caregivers. The alert processor sends different alerts re different patients; caregivers can determine from the alert which patient the alert is for. The server maintains information re wettings and alerts, and is independently accessible by users.
Aim: Specific learning disorder (SLD) is a term that refers to reading, writing and arithmetic difficulties. The neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and systemic inflammation index (SII) are affordable and accessible inflammatory biomarkers. This research aims to evaluate the relationship between NLR, PLR, SII and SLD to determine whether inflammation contributes to pathogenesis.Methods: This study included 90 SLD-diagnosed patients and 90 age-, sex- and ethnicity-matched healthy controls. Blood cell counts and NLR, PLR and SII values were obtained from medical records and compared between the two groups.Results: The NLR, PLR and SII were significantly higher (p = 0.029, p = 0.033 and p = 0.018 respectively) and lymphocyte counts were significantly lower (p = 0.041) in the SLD group. WISC-R total scores decreased with age in the SLD group (-1.988 coefficient, Beta = -0.247 ß, p = 0.041). Multivariate logistic regression analysis revealed that the SII was the only parameter independently associated with the diagnosis of SLD (Beta = 0.003, p = 0.023).Conclusion: Inflammation might play a role in SLD etiopathogenesis. NLR, PLR and SII may be potential biomarkers for SLD in children. Further research may lead to early diagnosis and additional anti-inflammatory pharmacological therapies for SLDs.